SHIM
SNDX icon

Stone House Investment Management’s Syndax Pharmaceuticals SNDX Stock Holding History

Stone House Investment Management’s Portfolio SNDX Stock Details SNDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$44 Sell
2
-76
-97% -$1.58K ﹤0.01% 1321
2026
Q1 		$1.82K Buy
+78
New +$1.7K ﹤0.01% 607

Other funds holding SNDX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.81B AUM 192.15% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
EP
Eversept Partners New York $1.93B AUM 160.8% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
HRCM
Hood River Capital Management Palm Beach Gardens, Florida $13.8B AUM 163.97% 1-Year Est. Return

Stone House Investment Management's SNDX Position: Q2 2026 in Review

Stone House Investment Management reduced its Syndax Pharmaceuticals (SNDX) stake by 97% in Q2 2026, selling an estimated $1.58K and leaving 2 shares worth $44. The position accounts for ﹤0.01% of the portfolio, ranked #1321.

Stone House Investment Management first reported a position in SNDX in Q1 2026 and has held it in 2 quarters since. The position peaked at $1.82K in Q1 2026. 242 funds tracked by Wall St. Rank hold SNDX as of Q2 2026.

  • Stone House Investment Management held 2 shares of Syndax Pharmaceuticals worth $44 as of Q2 2026.
  • Stone House Investment Management sold 76 Syndax Pharmaceuticals shares in Q2 2026, an estimated $1.58K.
  • Syndax Pharmaceuticals made up ﹤0.01% of Stone House Investment Management's portfolio in Q2 2026, its #1321 holding.
  • Stone House Investment Management first reported a position in Syndax Pharmaceuticals in Q1 2026 and has held it in 2 quarters since.
  • Stone House Investment Management's Syndax Pharmaceuticals position peaked at $1.82K in Q1 2026.
  • 242 funds tracked by Wall St. Rank held Syndax Pharmaceuticals as of Q2 2026.

Based on Stone House Investment Management's 13F filing for Q2 2026, filed 5 Aug 2026.